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Summary
 
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by
deposition of autoantibodies at the basement membrane zone. In an experimental BP model in
mice, the subepidermal blistering is mediated by antibodies directed against the hemidesmo-
somal protein BP180 (collagen XVII, BPAG2), and depends on complement activation and
neutrophil infiltration. Gelatinase B is present in BP blister fluid and can cleave BP180. In this
study we investigated the role of gelatinase B in the immunopathogenesis of experimental BP
using mice containing targeted disruption of the gelatinase B (MMP-9, 92 kD gelatinase) gene.
Gelatinase B–deficient mice were resistant to the blistering effect of intracutaneous anti-
mBP180 antibodies, although these mice showed deposition of autoantibodies at the basement
membrane zone and neutrophil recruitment to the skin comparable to that observed in the
control mice. Interleukin 8 given intradermally concomitantly with pathogenic anti-mBP180
elicited a significant neutrophil recruitment into the skin in gelatinase B–deficient mice, but
blistering did not occur. However, gelatinase B–deficient mice reconstituted with neutrophils
from normal mice developed blistering in response to anti-mBP180 antibodies. These results
implicate neutrophil-derived gelatinase B in the pathogenesis of experimental BP and might
lead to novel therapeutic strategies for BP.
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ullous pemphigoid (BP)
 
1
 
 is an autoimmune subepider-
mal blistering disorder characterized by deposition of
autoantibodies at the basement membrane zone (BMZ),
complement activation, and inflammatory cell infiltration
(1). BP autoantibodies are directed against two major
hemidesmosomal components, the 230-kD intracellular
protein BP230 (2, 3) and the 180-kD transmembrane pro-
tein BP180 (BPAG2, HD4, or type XVII collagen) (4–8).
Histologic and ultrastructural studies show that the blisters
in BP occur within the lamina lucida of the basement
membrane (9, 10). It has been hypothesized that protein-
ases and reactive free radicals released from infiltrating in-
flammatory cells contribute to the tissue damage in BP le-
sions (11, 12). BP blister fluids and lesional/perilesional sites
contain serine proteinases including neutrophil elastase,
plasmin, plasminogen activators, and matrix metallopro-
teinases including gelatinase A (72-kD gelatinase; matrix
metalloproteinase [MMP]-2) and gelatinase B (92-kD ge-
latinase; MMP-9) (13–19). However, the role of each of
these enzymes in the pathogenesis of BP is unclear.
Gelatinase B is normally expressed by neutrophils, mac-
rophages, osteoclasts, and trophoblasts (20). It cleaves a
number of extracellular matrix proteins, including entactin,
aggrecan, pepsinized type IV collagen, and elastin (21–24).
It also acts on various nonmatrix macromolecules, includ-
ing 
 
a
 
1
 
 protease inhibitor (
 
a
 
1
 
-PI), galactoside-binding pro-
teins, IL-1
 
b
 
, and substance P (20). Gelatinase B is an abun-
dant component of BP blister fluid and is localized to BP
lesional sites (19). Furthermore, gelatinase B cleaves the ex-
tracellular, collagenous domain of recombinant BP180 an-
tigen (19). These data suggest that gelatinase B plays an im-
portant role in BP.
 
1
 
Abbreviations used in this paper:
 
 
 
a
 
1
 
-PI, 
 
a
 
1
 
 proteinase inhibitor; APMA,
 
p
 
-aminophenylmercuric acetate; BMZ, basement membrane zone; BP,
bullous pemphigoid; IF, immunofluorescence; mBP180, murine BP180
antigen; MMP, matrix metalloproteinase; MPO, myeloperoxidase.
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Recently, we described a murine model that recapitu-
lates the key immunohistological features of human BP
(25). Subepidermal blister formation, which is triggered by
anti–murine BP180 IgG (anti-mBP180), is dependent on
complement activation and neutrophil infiltration (26, 27).
In this study we assessed whether gelatinase B plays a role
in the pathogenesis of experimental BP using a strain of
mice lacking this enzyme as a result of targeted mutagenesis.
 
Materials and Methods
 
Materials.
 
PMSF, 1,10-phenanthroline, and gelatin were ob-
tained from Sigma Chemical Co. (St. Louis, MO). Human my-
eloperoxidase (MPO) was purchased from Athens Research and
Technology, Inc. (Athens, Georgia). Monospecific FITC-conju-
gated goat anti–rabbit IgG was obtained from Kirkegaard & Perry
Laboratories, Inc. (Gaithersburg, MD). Monospecific goat anti–
mouse C3 was purchased from Cappel Laboratories (Durham, NC).
 
Laboratory Animals.
 
Breeding pairs of BALB/c and C57BL/6J
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME) and maintained at the Medical College of Wisconsin Animal
Resource Center. Gelatinase B
 
2
 
/
 
2
 
 and matched normal control
(gelatinase B
 
1
 
/
 
1
 
) mice were generated as described previously
(28). Neonatal mice, 24–36-h-old, weighing 1.4–1.6 g, were
used for passive transfer experiments.
 
Preparation of Pathogenic Rabbit Anti–murine BP180 IgG.
 
The pre-
paration of recombinant murine BP180 and the immunization of
rabbits were performed as previously described (25). In brief, a
segment of the murine BP180 antigen encompassing amino acids
495–643 of the ectodomain of this protein (29) was expressed as a
glutathione S-transferase (GST) fusion protein using the pGEX
prokaryotic expression system (Pharmacia Biotech, Piscataway,
NJ). The murine BP180 fusion protein, designated GST-
mBP180ABC, was purified to homogeneity by affinity chroma-
tography (30). New Zealand White rabbits were immunized with
the purified murine BP180 fusion protein and the IgG fraction
from the sera was purified as previously described (25). The titers
of rabbit anti–murine BP180 antibodies in the rabbit sera and in
the purified IgG fractions were assayed by indirect immunofluo-
rescence (IF) using mouse skin cryosections as substrate as re-
ported elsewhere (25). The pathogenicity of IgG preparations was
tested by passive transfer experiments. One pathogenic anti-
mBP180 IgG (referred to as R621) and one control IgG (referred
to as R50) were used.
 
Induction of Experimental BP and Clinical Evaluation.
 
Neonates were
given one intradermal injection (50 
 
m
 
l each, 2.5 mg/g body
weight) of a sterile solution of IgG in PBS. The injection tech-
niques have been described elsewhere (25, 31, 32). The skin of
neonatal mice from the test and control groups was examined 12 h
after the IgG injections. The activity of cutaneous disease was
scored as follows: (
 
2
 
), no detectable skin disease; 1
 
1
 
, mild
erythematous reaction with no evidence of “epidermal detach-
ment” (epidermal detachment was elicited by gentle friction of
the skin that, when positive, produced fine, persistent wrinkling
of the epidermis); 2
 
1
 
, intense erythema and epidermal detach-
ment involving 10–50% of the epidermis in the injection site; and
3
 
1
 
, intense erythema with frank epidermal detachment involving
 
.
 
50% of the epidermis in the injection site. In some experi-
ments, neonatal gelatinase B
 
2
 
/
 
2
 
 and B
 
1
 
/
 
1
 
 mice were coinjected
with human recombinant IL-8 (100 ng) and pathogenic anti-
mBP 180 IgG (2.5 mg/g body weight). After 12 h the skin was
examined and biopsied for histological examination and quantifi-
cation of PMN by MPO assay as described below.
 
Immunohistochemistry.
 
After clinical examination the animals
were killed. Skin sections were taken for light microscopy (hema-
toxylin and eosin staining) and direct IF to detect rabbit IgG and
mouse C3 deposition at the BMZ, and sera was obtained for indi-
rect IF analysis to determine the circulating titers of anti-BP180
IgG. Direct and indirect IF analyses were performed as previously
described (25, 31, 32).
 
Quantification of Skin Site PMN Accumulation.
 
Tissue MPO ac-
tivity in skin sites of the injected animals was assayed as previously
described (33). A standard reference curve was first established by
measuring known concentrations of purified MPO. The skin sites
were excised and extracted by homogenization in an extraction
buffer containing 0.1 M Tris-Cl, pH 7.6, 0.15 M NaCl, and 0.5%
hexadecyl trimethyl ammonium bromide. MPO activity in su-
pernatants was measured by the change in optical density (OD) at
460 nm resulting from decomposition of H
 
2
 
O
 
2
 
 in the presence of
 
o
 
-dianisidine. MPO content was expressed as relative MPO activ-
ity (OD
 
460nm
 
 reading/mg protein). Protein concentrations were
determined by the Bio-Rad dye binding assay (Bio-Rad, Her-
cules, CA) using BSA as a standard.
 
Gelatin Zymography.
 
Gelatinase profiles were determined by
zymography as described previously (34). In brief, protein ex-
tracts of neutrophils and skin sections from injected animals were
subjected to SDS-PAGE on gelatin-containing acrylamide gels
(10% acrylamide and 1% gelatin) under nonreducing conditions.
After electrophoresis, gels were washed twice with 2.5% Triton
X-100 for 30 min to remove SDS. Gels were then rinsed briefly
with water followed by incubation overnight at 37
 
8
 
C in reaction
buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, and 5 mM
CaCl
 
2
 
. The gels were stained with 0.125% Coomassie Brilliant
blue. Areas of gelatinolytic activity appeared as clear zones against
a dark blue backgound.
To determine the class of proteinases visualized on zymograms,
samples were mixed with inhibitors or the solvent used for the
inhibitor and incubated for 15 min at room temperature before
electrophoresis. The final concentrations of inhibitors used were
1 mM PMSF (isopropanol as the solvent), 5 mM EDTA (water as
the solvent), and 10 mM 1,10-phenanthroline (methanol as sol-
vent). After electrophoresis, the gels were washed in 2.5% Triton
X-100, incubated in reaction buffer, and stained with 0.125%
Coomassie Brilliant blue as described above.
 
Neutrophil Isolation and Extraction.
 
Neutrophils were isolated
from heparinized blood by dextran sedimentation followed by
separation on a density gradient as previously described (35). In
brief, the blood from adult animals was drawn by cardiac punc-
ture into syringes containing heparin (20 U/ml). After sedimenta-
tion in an equal volume of 3% Dextran T 500 (Pharmacia Biotech
AB, Uppsala, Sweden) in PBS for 20 min at room temperature,
the leukocyte-rich layer was washed in PBS and layered over
Ficoll-Hypaque (Pharmacia Biotech AB). The neutrophils and
mononuclear cells were separated by centrifugation for 40 min at
400 
 
g
 
 at 20
 
8
 
C. Red blood cells were then removed from the cell
preparation by hypotonic lysis in 0.2% NaCl. Neutrophils were
washed and resuspended in cold PBS/10 mM glucose, counted in
a hemocytometer, and adjusted to a concentration of 10
 
7
 
 cells/ml.
Neutrophil purity of the final cell preparation was consistently
 
.
 
96% as determined by cell-cytospin and LeukoStat staining
(Fisher Diagnostics, Orangeburg, NY). The viability of the neu-
trophils was 
 
.
 
96% as determined by trypan blue exclusion. The
purified neutrophils were homogenized and extracted in the same
manner as described for skin samples. 
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In Vivo Reconstitution of Neutrophil Gelatinase B.
 
Gelatinase B
 
2
 
/
 
2
 
mice were injected intradermally with pathogenic anti-mBP180
IgG (2.5 mg/100 
 
m
 
l PBS). 2 h later, these mice received 5 
 
3
 
 10
 
5
 
neutrophils intradermally (in 50 
 
m
 
l of PBS/10 mM glucose) at the
same site. The neutrophils were purified from gelatinase B
 
2
 
/
 
2
 
 or
gelatinase B
 
1
 
/
 
1
 
 mice. 12 h after the IgG injections the animals
were analyzed as described above.
 
Statistical Analysis.
 
The data were expressed as mean 
 
6
 
 SEM
and were analyzed using Student’s 
 
t
 
 test. 
 
P
 
 
 
,
 
0.05 was considered
significant.
 
Results
 
Gelatinase B Is Present in Experimental BP Blisters.
 
Gelati-
nase B is abundant in blister fluid from patients with BP
(19). To determine if gelatinase B was present in the sub-
epidermal blisters of experimental BP, control BALB/c
mice were injected with pathogenic rabbit anti-mBP180
IgG and lesional skin samples were analyzed by gelatin zy-
mography. A prominent gelatinolytic band migrating at 97 kD
was present only in lesional skin of mice injected with
pathogenic anti-mBP180 IgG, R621 (Fig. 1, lane 
 
3
 
). This
gelatinolytic band comigrated with murine gelatinase B
(Fig. 1, lane 
 
4
 
). The zymogen of the enzyme (
 
pro
 
) was con-
verted to smaller fragments (
 
act
 
) by organomercurial activa-
tion (
 
p
 
-aminophenylmercuric acetate [
 
APMA
 
]) (Fig. 1,
lane 
 
11
 
). No gelatinolytic band at 97 kD was present in
samples from mice injected with PBS (Fig. 1, lane 
 
1
 
) or
control IgG R50 (Fig. 1, lane 
 
2
 
). In all skin samples, gelati-
nolytic activities were also detected at 69, 64, and 50 kD,
presumably due to gelatinase A (MMP-2; 72-kD gelati-
nase), which is expressed by fibroblasts. All of the gelati-
nolytic activities could be blocked by 5 mM EDTA (Fig. 1,
lanes 
 
5–7
 
) and 1,10-phenanthroline (data not shown), which
inhibit matrix metalloproteinases, but not by the serine
proteinase inhibitor PMSF (Fig. 1, lanes 
 
8–10
 
). These find-
ings confirmed that the 97-kD gelatinase (gelatinase B), was
associated with subepidermal blister formation in experi-
mental BP, most likely from infiltrating neutrophils.
 
Gelatinase B–deficient Mice Are Resistant to the Pathogenic Ac-
tivity of Anti-mBP180 Antibodies.
 
To directly assess whether
gelatinase B is involved in subepidermal blister formation in
experimental BP, gelatinase B
 
1
 
/
 
1
 
 and gelatinase B
 
2
 
/
 
2
 
 mice
were injected intradermally with pathogenic anti-BP180
IgG (2.5 mg/g body weight). BALB/c mice were also used
as a positive control. As expected, gelatinase B
 
1
 
/
 
1
 
 mice (
 
n
 
 
 
5
 
9) and the BALB/c controls (Table 1) developed extensive
blisters 12 h after injection with anti-mBP180 IgG (Fig. 2
 
A
 
). The skin of these animals was markedly erythematous
and developed persistent epidermal wrinkling due to the
detachment of the epidermis from the underlying dermis.
Direct IF on cryosections of lesional/perilesional skin of
the mice showed in situ deposition of rabbit anti-mBP180
IgG (Fig. 2 
 
B
 
) and mouse C3 (Fig. 2 
 
C
 
) at the BMZ, der-
mal–epidermal separation, and neutrophilic infiltration
(Fig. 2 
 
D
 
). In contrast, gelatinase B
 
2
 
/
 
2
 
 mice (
 
n
 
 
 
5
 
 9) exhib-
ited no blisters 12 h after injection with anti-mBP180 IgG
(Fig. 2 
 
E
 
), although they had a comparable level of circu-
lating rabbit IgG (data not shown) to the wild-type mice,
and direct IF showed in situ deposition of rabbit IgG (Fig.
2 
 
F
 
) and mouse C3 (Fig. 2 
 
G
 
) at the BMZ. The skin sec-
tions from gelatinase B
 
2
 
/
 
2
 
 mice exhibited neutrophilic in-
Figure 1. Gelatin zymography of lesional skin in experimental BP.
Skin samples (12 mg/lane) from BALB/c mice injected with PBS (lane 1),
control rabbit IgG R50 (lanes 2, 5, and 8), or pathogenic anti-mBP180
IgG R621 (lanes 3, 6, 9, and 11) were analyzed by gelatin zymography.
Purified murine neutrophil extract was used as a standard (1 mg/lane;
lanes 4, 7, and 10). A 97-kD gelatinolytic band was seen in lesional skin
samples of mice injected with R621 (lane 3) but not in samples from mice
injected with PBS or R50 controls (lanes 1 and 2). This band comigrates
with the proenzyme form of gelatinase B (pro) seen in purified PMN (lane
4). Gelatinase activities in lanes 2–4 were completely inhibited by the
metalloproteinase inhibitor EDTA (lanes 5–7) but not by the serine pro-
teinase inhibitor PMSF (lanes 8–10). The gelatinase B activity was con-
verted to lower molecular weight species after treatment with APMA, an
activator of matrix metalloproteinases (lane 11).
Table 1. Summary of the Role of Gelatinase B in
Experimental BP
Host mice*
IgG 
injected Treatment
Number
of mice
Disease
activity‡
BALB/c R50 2 9 2
R621 2 12 31
Gelatinase B1/1 R50 2 8 2
R621 2 14 31
Gelatinase B2/2 R621 – 16 2
R621 1mPMN(2/2)5 2
R621 1mPMN(1/1)5 2 1
R621 1 IL-8 5 2
*Neonatal BALB/c, gelatinase B-sufficient (gelatinase B1/1), and ge-
latinase B-deficient (gelatinase B2/2) mice were injected intradermally
with either control IgG (R50) or pathogenic anti-mBP180 antibody
(R621). Purified mouse neutrophils (5 3 105 cells/50 ml) from either
gelatinase B2/2 [mPMN(2/2)] or gelatinase B1/1 [mPMN(1/1)]
mice were given intradermally 2 h after IgG injection.
‡Injected animals were examined clinically 12 h after IgG injection.
Disease activity is scored on a scale of 2 to 31. 2 means no detectable
skin lesion; 21 means intense erythema and epidermal detachment in-
volving 10–50% of the epidermis at the injection site; 31 means intense
erythema with frank epidermal detachment involving .50% of the epi-
dermis at the injection site. See Materials and Methods for details.478 Gelatinase B in Experimental Bullous Pemphigoid
filtration, but no dermal–epidermal separation (Fig. 2 H).
As expected, skin extracts from gelatinase B2/2 mice,
which did not form blisters after pathogenic anti-mBP180
IgG, did not show gelatinase B activity (data not shown).
MPO activity, a method of quantifying neutrophil infil-
tration, was similar in the skin at the IgG-injected sites of
gelatinase B2/2, gelatinase B1/1, and BALB/c control mice
at 4 h after injection (Fig. 3, bars 1, 3, and 5). However,
significant differences (P ,0.001) in the extractable MPO
activity were observed at 12 h after injection. Gelatinase
B2/2 skin extracts showed approximately half as much
MPO activity as controls (Fig. 3, bars 2, 4, and 6). These
data indicate that neutrophil gelatinase B deficiency did not
prevent neutrophil recruitment during the initial 4-h pe-
riod after intradermal pathogenic anti-mBP180 IgG injec-
tion. This is important because the onset of blister forma-
tion in gelatinase B1/1 mice is seen in this 4-h period. The
higher MPO values at 12 h in control mice are consistent
with the development of tissue injury in the skin of these
animals leading to additional neutrophil recruitment be-
tween 4 and 12 h.
To determine whether gelatinase B participates in the
immunopathology of BP or in neutrophil recruitment from
the circulation into inflammatory sites, gelatinase B2/2 (n 5
5) and gelatinase B1/1 (n 5 5) mice were coinjected intra-
dermally with a neutrophil chemoattractant, IL-8 (100 ng/
mouse), and pathogenic anti-mBP180 IgG (2.5 mg/g body
weight). These animals were examined 12 h after injection
(Table 1). Although the IL-8 resulted in higher levels of
MPO activity in the skin of the gelatinase B2/2 (1.49 6
0.21), comparable to positive control mice (1.19 6 0.11),
the gelatinase B2/2 mice still showed no clinical or histo-
logical signs of blistering (data not shown). These data indi-
cate that gelatinase B plays a direct role in the events leading
to blister formation in experimental BP, after neutrophils
are recruited into the skin.
Pathogenic Anti-mBP180 Antibodies Induce BP Blisters in
Gelatinase B2/2 Mice Reconstituted with Normal Neutro-
phils. If gelatinase B released from neutrophils is directly
involved in the tissue injury in experimental BP, then ge-
latinase B2/2 mice reconstituted with normal neutrophils
should develop subepidermal blisters when challenged with
the pathogenic anti-mBP180 IgG. Therefore, gelatinase
B2/2 mice (n 5 5) were injected intradermally with patho-
genic anti-mBP180 IgG and 2 h later received an intrader-
mal injection of 5 3 105 neutrophils isolated from either
gelatinase B2/2 or gelatinase B1/1 mice. Mice reconsti-
tuted with neutrophils from gelatinase B2/2 mice showed
no skin lesions (Fig. 4, A and B; Table 1). In contrast, mice
reconstituted with neutrophils from gelatinase B1/1 mice
Figure 2. Clinical and histological evaluation of neo-
natal gelatinase B2/2 and gelatinase B1/1 mice injected
with pathogenic anti-mBP180 IgG. Pathogenic rabbit
anti–murine BP180 IgG R621 (intradermal injection,
2.5 mg/g body weight) produced extensive epidermal
blistering in neonatal gelatinase B1/1 mice (A). The
skin of these animals showed linear deposition of
R621 (B) and mouse C3 (C) at the BMZ by direct IF.
Hematoxylin and eosin (H&E) staining of skin from
these mice showed subepidermal vesicle formation
with neutrophilic infiltration (D). The inset, a higher
magnification of D, demonstrates a neutrophil at the
lesional site in the dermis. In contrast, neonatal gelati-
nase B2/2 mice injected intradermally with R621 IgG
showed no clinical evidence of skin disease (E). Direct
IF studies showed rabbit R621 IgG deposition (F) and
mouse C3 (G) at the BMZ. These animals exhibited
neutrophilic infiltration, but no evidence of subepi-
dermal vesiculation at the light microscopic level (H)
by H&E staining. The inset, a higher magnification of
H, exhibits a neutrophil underneath the basal kerati-
nocyte. Site of antibody labeling (white arrows), basal
keratinocyte (black arrows). d, dermis; e, epidermis; v,
vesicle. Original magnification: 3100. Insets (original
magnification 3400): neutrophil (black arrowheads).479 Liu et al.
developed typical BP skin lesions (Fig. 4 C) with dermal-
epidermal separation (Fig. 4 D). The lack of gelatinase B
had no effect on neutrophil survival in the skin. The reten-
tion of exogenous neutrophils in the skin was similar in
both gelatinase B1/1 and gelatinase B2/2 mice, as deter-
mined by MPO activity (data not shown).
Gelatin zymography revealed that gelatinase B2/2 mice
reconstituted with gelatinase B-deficient neutrophils showed
no gelatinase B activity in the protein extracts of skin of
mice injected with normal control IgG (Fig. 5, lane 1) or
pathogenic IgG (Fig. 5, lane 2). These mice did not de-
velop disease. In contrast, gelatinase B2/2 mice reconsti-
tuted with gelatinase B-sufficient neutrophils exhibited
high levels of gelatinase B activity in protein extracts of skin
of mice injected with control IgG (Fig. 5, lane 3) or patho-
genic IgG (Fig. 5, lane 4). However, only pathogenic anti-
mBP180 IgG but not control IgG induced clinical disease
in gelatinase B2/2 mice reconstituted with normal neutro-
phils. This is because pathogenic antibodies but not control
IgG bind to the basement membrane zone in situ, trigger
neutrophil degranulation and elicit experimental BP when
normal neutrophils are present. Taken together, these re-
sults further demonstrate the requirement for release of
neutrophil gelatinase B into the BMZ to trigger the patho-
genesis of experimental BP.
Discussion
Experimental BP in mice involves passive immunization
with pathogenic anti-mBP180 IgG to trigger subepidermal
blistering (25). We have previously found that blister for-
mation depends on complement activation (26) and neu-
trophil recruitment into the dermis (27). The neutrophil
infiltration is temporally and spatially related to subepider-
mal blister formation, whereas blockage of neutrophil re-
cruitment into the skin site completely inhibits the patho-
genic activity of anti-mBP180 antibodies (27). The central
role of infiltrating neutrophils in the tissue injury in experi-
mental BP led us to investigate which neutrophil compo-
nents are involved in the development of the disease. In
this study we demonstrate that gelatinase B released from
neutrophils plays an essential role in subepidermal blister
formation in experimental BP based on the following find-
ings: (a) a significant level of gelatinase B is present in le-
Figure 3. MPO activity of skin extracts from mice injected intrader-
mally with pathogenic rabbit anti-mBP180 IgG. Neonatal gelatinase B2/2
(bars 1 and 2), gelatinase B1/1 (bars 3 and 4), and BALB/c (bars 5 and 6)
mice received 2.5 mg/g body weight anti-mBP180 IgG R621. Tissue
MPO activities (mean 6 SEM) in the injection sites were determined 4
(bars 1, 3, and 5) and 12 (bars 2, 4, and 6) h after the IgG injection. n 5 8
for each group. *P ,0.001, Student’s t test for paired samples: (bar 2 ver-
sus 4). 0.58 6 0.06 versus 1.27 6 0.11 (P ,0.001) and versus 1.19 6
0.16, respectively (P ,0.001). The MPO values shown were corrected
for PBS controls. Each group of mice injected with PBS yielded an aver-
age of MPO activity of z0.1 OD460nm/mg protein.
Figure 4. Experimental BP in gelatinase B2/2 mice
reconstituted with normal neutrophils. Pathogenic rab-
bit anti-mBP180 IgG R621 (intradermal injection, 2.5
mg/g body weight) did not induce blisters in neonatal
gelatinase B2/2 mice reconstituted with neutrophils
from gelatinase B2/2 mice [A, mPMN(2/2)]. The
skin of these animals showed no dermal–epidermal sep-
aration by H&E (B). In contrast, the pathogenic R621
IgG triggered separation in neonatal gelatinase B2/2
mice reconstituted with neutrophils from gelatinase
B1/1 mice [C, mPMN(1/1)]. H&E-stained section
from these mice showing a subepidermal vesicle (D). d,
dermis; e, epidermis; v, vesicle. Original magnification:
3100.480 Gelatinase B in Experimental Bullous Pemphigoid
sional skin of BP mice; (b) gelatinase B2/2 mice are resis-
tant to experimental BP; and (c) gelatinase B2/2 mice
reconstituted with gelatinase B1/1 neutrophils develop ex-
perimental BP (Table 1).
Gelatinase B is expressed by inflammatory cells, includ-
ing neutrophils, macrophages, and eosinophils (20). Our
data suggest that the major source of gelatinase B in mouse
lesional skin is neutrophils. Gelatinase B is not seen in skin
from noninjected animals or noninvolved skin in experi-
mental BP. In contrast, gelatinase B is observed z3 h after
injection of pathogenic anti-mBP180 IgG, which coincides
with the beginning of subepidermal blistering. Gelatinase B
is temporally and spatially associated with neutrophil infil-
tration and subsequent dermal-epidermal separation. The
major source of gelatinase B in human BP lesions and blis-
ter fluid is infiltrating eosinophils, and to a lesser extent
neutrophils (19). Although eosinophils are not present in
the early phases of subepidermal blistering in experimental
BP in mice (25–27), gelatinase B produced by eosinophils
may play a secondary role in the later stages of experimen-
tal BP blister formation.
MMPs have been implicated in cell migration during tis-
sue regeneration, wound healing, and inflammation (36).
Decreased human neutrophil migration across Matrigel-
coated micropore filters has been observed in the presence
of MMP inhibitors, suggesting that gelatinase B, which is
readily released from neutrophils, could be important in
transmigration of these cells from the circulation (37).
However, the resistance of gelatinase B2/2 mice to experi-
mental BP was not due to impaired neutrophil recruit-
ment. There was no difference in neutrophil recruitment
between gelatinase B2/2 and gelatinase B1/1 mice 4 h after
the injection of pathogenic IgG, when blister formation has
already begun in gelatinase B1/1 mice. Increasing neutro-
phil recruitment in gelatinase B2/2 mice to the level seen
in gelatinase B1/1 at 12 h by the intradermal coinjection of
IL-8 and pathogenic antibodies did not induce BP blister-
ing. In addition, gelatinase B2/2 mice also have normal
neutrophil recruitment into the lungs and the peritoneal
cavity (Senior, R.M., unpublished observation). Moreover,
the pathogenic anti-BP180 IgG induced blistering in ge-
latinase B2/2 mice reconstituted with neutrophils from ge-
latinase B1/1 mice, but not with neutrophils from gelati-
nase B2/2 mice. Taken together, these data demonstrate
that gelatinase B deficiency does not impair neutrophil mi-
gration into the skin and implicate neutrophil-derived ge-
latinase B directly in the subepidermal blistering of experi-
mental BP.
Gelatinase B has a broad substrate specificity for extracel-
lular matrix proteins, including entactin, aggrecan, pep-
sinized type IV collagen, elastin (20–24), the extracellular
domain of recombinant BP180 (19), and nonmatrix pro-
teins such as a1-PI (20). Thus, gelatinase B could contrib-
ute to tissue damage in BP directly by cleaving structural
proteins in the dermal–epidermal junction, or indirectly by
inactivating a1-PI, the principal neutrophil elastase inhibi-
tor, or other inhibitors of other neutrophil-derived pro-
teolytic enzymes that may also contribute to the long term
pathogenesis (38, 39). Determining which gelatinase B sub-
strates are critical in the dermal–epidermal detachment will
allow further dissection of the immunopathological mecha-
nisms of subepidermal blister formation in BP and aid in
the development of more effective therapeutic strategies for
this autoimmune skin disorder.
This work was supported in part by U.S. Public Health Service National Institutes of Health grants R29 AI-
40768 (Z. Liu), R01 AR-32599 and R37 AR-32081 (L.A. Diaz), R01 HL-47328 (R.M. Senior), and P60
AR-20684 and P01 CA-72006 (Z. Werb); by a Veterans Affairs Merit Review Grant (L.A. Diaz); and by
the Alan A. and Edith L. Wolff Charitable Trust (R.M. Senior). Z. Liu was the recipient of a Dermatology
Figure 5. Gelatin zymography of lesional skin samples of gelatinase B2/2
mice reconstituted with normal neutrophils. Neonatal gelatinase B2/2
mice received intradermally 2.5 mg/g body weight of control IgG R50
(lanes 1 and 3), or pathogenic anti-mBP180 IgG R621 (lanes 2 and 4). 2 h
later, these mice were injected at the same site with 5 3 105 neutrophils
purified from gelatinase B2/2 mice [mPMN(2/2); lanes 1 and 2], or ge-
latinase B1/1 mice [mPMN(1/1); lanes 3 and 4]. 12 h after IgG injec-
tions, these animals were examined for blistering, and skin biopsies at the
injection site were analyzed by gelatin zymography (12 mg/lane). Purified
control murine neutrophil extract (1 mg; lane 5) was used as a standard for
gelatinase B. Gelatinase B2/2 mice reconstituted with mPMN (2/2)
showed no disease and no gelatinase B in the skin samples when injected
with control R50 IgG (lane 1) or R621 IgG (lane 2). In contrast, gelati-
nase B2/2 mice reconstituted with mPMN(1/1) developed disease
when injected with R621 IgG (lane 4) but not control IgG R50 (lane 3).
Gelatinase B activity is seen when gelatinase B2/2 mice are reconstituted
with normal neutrophils (lanes 3 and 4).481 Liu et al.
Foundation Career Development Award and a Dermatology Foundation Research Grant sponsored by the
Burroughs Wellcome Fund. J.M. Shipley was a fellow of the Parker B. Francis Foundation. T.H. Vu was a
fellow of the American Lung Association, California Affiliate.
Address correspondence to Zhi Liu, Department of Dermatology, Medical College of Wisconsin, 8701 Wa-
tertown Plank Rd., Milwaukee, Wisconsin 53226. Phone: 414-456-4087; Fax: 414-456-6518; E-mail:
zhiliu@post.its.mcw.edu
Received for publication 1 April 1998 and in revised form 1 June 1998.
References
1. Anhalt, G.F., and L. Morrison. 1993. Pemphigoid: bullous,
gestational and cicatricial. In Bullous Diseases. T.T. Provost
and W.L. Weston, editors. Mosby Year Book, St. Louis,
MO. 63–114.
2. Tanaka, T., D.A. Parry, V. Klaus-Kovtun, P.M. Steinert, and
J.R. Stanley. 1991. Comparison of molecularly cloned bullous
pemphigoid antigen to desmoplakin I confirms that they de-
fine a new family of cell adhesion junction plaque proteins. J.
Biol. Chem. 266:12555–12559.
3. Sawamura, D., K. Li, M.-L. Chu, and J. Uitto. 1991. Human
bullous pemphigoid antigen (BPAG1). Amino acid sequences
deduced from cloned cDNAs predict biologically important
peptide segments and protein domains. J. Biol. Chem. 266:
17784–17790.
4. Diaz, L.A., H. Ratrie III, W.S. Saunders, S. Futamura, H.L.
Squiquera, G.J. Anhalt, and G.J. Giudice. 1990. Isolation of a
human epidermal cDNA corresponding to the 180-kD au-
toantigen recognized by bullous pemphigoid and herpes ges-
tationis sera. Immunolocalization of this protein to the
hemidesmosome.  J. Clin. Invest. 86:1088–1094.
5. Giudice, G.J., D.J. Emery, and L.A. Diaz. 1992. Cloning and
primary structural analysis of the bullous pemphigoid autoan-
tigen, BP-180. J. Invest. Dermatol. 99:243–250.
6. Nishizawa, Y., J. Uematsu, and K. Owaribe. 1993. HD4, a
180 kDa bullous pemphigoid antigen, is a major transmem-
brane glycoprotein of the hemidesmosome. J. Biochem. 113:
493–501.
7. Hopkinson, S.B., K.S. Riddelle, and J.C.R. Jones. 1992. Cy-
toplasmic domain of the 180-kD bullous pemphigoid anti-
gen, a hemidesmosomal component: molecular and cell bio-
logic characterization. J. Invest. Dermatol. 99:264–270.
8. Bedane, C., J.R. McMillan, S.D. Balding, P. Bernard, C.
Prost, J.-M. Bonnetblanc, L.A. Diaz, R.A.J. Eady, and G.J.
Giudice. 1997. Bullous pemphigoid and cicatricial pemphi-
goid autoantibodies react with ultrastructurally separable epitopes
on the BP180 ectodomain: evidence that BP180 spans the
lamina lucida. J. Invest. Dermatol. 108:901–907.
9. Schaumburg-Lever, G., C.E. Orfanos, and W.F. Lever. 1971.
Electron microscopic study of bullous pemphigoid. Arch.
Dermatol. 106:662–667.
10. Dvorak, A.M., M.C. Mihm, J.E. Osage, T.H. Kwan, K.F.
Austen, and B.U. Wintroub. 1982. Bullous pemphigoid, an
ultrastructural study of the inflammatory response: eosino-
phil, basophil and mast cell granule changes in multiple biop-
sies of one patient. J. Invest. Dermatol. 78:91–101.
11. Jordon, R.E., S. Kawana, and K.A. Fritz. 1985. Immuno-
pathologic mechanisms in pemphigus and bullous pemphi-
goid. J. Invest. Dermatol. 85:72s–78s.
12. Gammon, W.R. 1989. Immune complex and complement-
mediated leukocyte recruitment in bullous pemphigoid. Im-
munol. Ser. 46:509–525.
13. Oikarinen, A.I., J.J. Zone, A.R. Ahmed, U. Kiistala, and J.
Uitto. 1983. Demonstration of collagenase and elastase activ-
ities in blister fluids from bullous skin diseases. Comparison
between dermatitis herpetiformis and bullous pemphigoid. J.
Invest. Dermatol. 81:261–266.
14. Welgus, H.G., E.A. Bauer, and G.P. Stricklin. 1986. Elevated
levels of human collagenase inhibitor in blister fluids of di-
verse etiology. J. Invest. Dermatol. 87:592–596.
15. Grando, S.A., B.T. Glukhenky, G.N. Drannik, A.P. Kos-
tromin, and A.I. Chernyavsky. 1989. Cytotoxic proteinases
in blister fluid of pemphigus and pemphigoid patients. Int. J.
Tissue React. 11:195–201.
16. Grando, S.A., B.T. Glukhenky, G.N. Drannik, E.V. Ep-
shtein, A.P. Kostromin, and T.A. Korostash. 1989. Mediators
of inflammation in blister fluids from patients with pemphi-
gus vulgaris and bullous pemphigoid. Arch. Dermatol. 125:
925–930.
17. Gissler, H.M., M.M. Simon, and M.D. Kramer. 1992. En-
hanced association of plasminogen/plasmin with lesional epi-
dermis of bullous pemphigoid. Br. J. Dermatol. 127:272–277.
18. Kramer, M.D., and J. Reinartz. 1993. The autoimmune blis-
tering skin disease bullous pemphigoid. The presence of plas-
min/a2-antiplasmin complexes in skin blister fluid indicates
plasmin generation in lesional skin. J. Clin. Invest. 92:978–983.
19. Ståhle-Bäckdahl, M., M. Inoue, G.J. Giudice, and W.C.
Parks. 1994. 92-kD gelatinase is produced by eosinophils at
the site of blister formation in bullous pemphigoid and
cleaves the extracellular domain of recombinant 180-kD
bullous pemphigoid autoantigen. J. Clin. Invest. 93:2022–
2030.
20. Vu, T.H., and Z. Werb. 1998. Gelatinase B: structure, regu-
lation, and function. In Matrix Metalloproteinases. W.C.
Parks and R.P. Mecham, editors. Academic Press. San Diego,
CA. 115–148.
21. Welgus, H.G., E.G. Campbell, J.D. Cury, A.Z. Eisen, R.M.
Senior, S.M. Wilhelm, and G.I. Goldberg. 1990. Neutral
metalloproteinases produced by human mononuclear phago-
cytes. Enzyme profile, regulation, and expression during cel-
lular development. J. Clin. Invest. 86:1496–1502.
22. Hibbs, M.S, K.A. Hasty, J.M. Seyer, A.M. Kang, and C.L.
Mainardi. 1985. Biochemical and immunological character-
ization of secreted forms of human neutrophil gelatinase. J.
Biol. Chem. 260:2493–2500.
23. Senior, R.M, G.L. Griffin, C.J. Fliszar, S.D. Shapiro, G.I.
Goldberg, and H.G. Welgus. 1991. Human 92-kilodalton
and 72-kilodalton type IV collagenases are elastases. J. Biol.
Chem. 266:7870–7875.
24. Sires, U.I., G.L. Griffin, T. Broekelmann, R.P. Mecham, G.
Murphy, A.E. Chung, H.G. Welgus, and R.M. Senior.482 Gelatinase B in Experimental Bullous Pemphigoid
1997. Degradation of entactin by matrix metalloproteinases.
Susceptibility to matrilysin and identification of cleavage sites.
J. Biol. Chem. 268:2069–2074.
25. Liu, Z., L.A. Diaz, J.L. Troy, A.F. Taylor, D.E. Emery, J.A.
Fairley, and G.J. Giudice. 1993. A passive transfer model of
the organ-specific autoimmune disease, bullous pemphigoid,
using antibodies generated against the hemidesmosomal anti-
gen, BP180. J. Clin. Invest. 92:2480–2488.
26. Liu, Z., G.J. Giudice, S.J. Swartz, J.A. Fairley, G.O. Till, J.L.
Troy, and L.A. Diaz. 1995. The role of complement in ex-
perimental bullous pemphigoid. J. Clin. Invest. 95:1539–
1544.
27. Liu, Z., G.J. Giudice, X. Zhou, S.J. Swartz, J.L. Troy, J.A.
Fairley, G.O. Till, and L.A. Diaz. 1997. A major role for
neutrophils in experimental bullous pemphigoid. J. Clin. In-
vest. 100:1256–1263.
28. Vu, T.H., J.M. Shipley, G. Bergers, J.E. Berger, J. Helms, D.
Hanahan, S.D. Shapiro, R.M. Senior, and Z. Werb. 1998.
Gelatinase B–null mice exhibit deficient growth plate angio-
genesis and hypertrophic chrondrocyte apoptosis. Cell. 93:
411–422.
29. Li, K., K. Tamai, E.M.L. Tan, and J. Uitto. 1993. Cloning of
type XVII collagen. Complementary and genomic DNA se-
quences of mouse 180-kilodalton bullous pemphigoid anti-
gen (BPAG2) predict an interrupted collagenous domain, a
transmembrane segment, and unusual features in the 59-end
of the gene and the 39-untranslated region of the mRNA. J.
Biol. Chem. 268:8825–8834.
30. Liu, Z., L.A. Diaz, A.L. Haas, and G.J. Giudice. 1992. cDNA
cloning of a novel human ubiquitin carrier protein. An anti-
genic domain specifically recognized by endemic pemphigus
foliaceus autoantibodies is encoded in a secondary reading
frame of this human epidermal transcript. J. Biol. Chem. 267:
15829–15835.
31. Anhalt, G.J., R.S. Labib, J.J. Voorhees, T.F. Beals, and L.A.
Diaz. 1982. Induction of pemphigus in mice by passive trans-
fer of IgG from patients with the disease. N. Engl. J. Med.
306:1189–1196.
32. Roscoe, J.T., L.A. Diaz, S.A.P. Sampaio, R.M. Castro, R.S.
Labib, H. Patel, and G.J. Anhalt. 1985. Brazilian pemphigus
foliaceus autoantibodies are pathogenic to BALB/c mice by
passive transfer. J. Invest. Dermatol. 85:538–541.
33. Bradley, P.P., D.A. Priebat, R.D. Christensen, and G. Roth-
stein. 1982. Measurement of cutaneous inflammation: esti-
mation of neutrophil content with an enzyme marker. J. In-
vest. Dermatol. 78:206–209.
34. Twining, S.S., X. Zhou, D.P. Schulte, P.M. Wilson, B. Fish,
and J. Moulder. 1996. Effect of vitamin A deficiency on the
early response to experimental Pseudomonas keratitis. Invest.
Ophthalmol. Vis. Sci. 37:511–522.
35. Clark, R.A., and W.M. Nauseef. 1994. Isolation and func-
tional analysis of neutrophils. In Current Protocols in Immu-
nology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M.
Shevach, and W. Strober, editors. John Wiley and Sons, Inc.,
New York, NY. 7.23.1–7.23.17.
36. Matrisian, L.M. 1990. Metalloproteinases and their inhibitors
in matrix remodeling. Trends Genet. 6:121–125.
37. Delclaux, C., C. Delacourt, M.-P. d’Ortho, V. Boyer, C.
Lafuma, and A. Harf. 1996. Role of gelatinase B and elastase
in human polymorphonuclear neutrophil migration across
basement membrane. Am. J. Respir. Cell Mol. Biol. 14:288–295.
38. Weiss, S.J. 1989. Tissue destruction by neutrophils. N. Engl.
J. Med. 320:365–376.
39. Ottonello, L., P. Dapino, and F. Dallegri. 1993. Inactivation
of a1-proteinase inhibitor by neutrophil metalloproteinases.
Crucial role of the myeloperoxidase system and effects of the
anti-inflammatory drug nimesulide. Respiration. 60:32–37.